Vanguard Capital Management
ABOS icon

Vanguard Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Vanguard Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46M Buy
1,672,072
+165,795
+11% +$410K ﹤0.01% 3168
2026
Q1 		$3.55M Buy
+1,506,277
New +$3.84M ﹤0.01% 3183

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management's ABOS Position: Q2 2026 in Review

Vanguard Capital Management increased its Acumen Pharmaceuticals (ABOS) stake by 11% in Q2 2026, buying an estimated $410K and bringing the position to 1,672,072 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3168.

Vanguard Capital Management first reported a position in ABOS in Q1 2026 and has held it in 2 quarters since. 91 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Vanguard Capital Management held 1,672,072 shares of Acumen Pharmaceuticals worth $4.46M as of Q2 2026.
  • Vanguard Capital Management bought 165,795 Acumen Pharmaceuticals shares in Q2 2026, an estimated $410K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3168 holding.
  • Vanguard Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 91 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.